نتائج البحث 841-850 من 4961 لعملية البحث عن Blood factor II
In the phase II part, to evaluate the preliminary antitumor activity of two different doses/regimens of [177Lu]Lu-NeoB in combination with capecitabine (dose ...
erapy, Growth factor drug therapy, Anemia, Immune ... Shaikh, M.D.. التصفّح البحث عن طبيب. توجّه للصفحة 11 · توجّه للصفحة 22 ... http://www.redcrossblood.org/learn- ...
... blood samples from patients undergoing coronary angiograms. ... 2. To identify potential pathways to ... توجّه للصفحة 22 · توجّه للصفحة 33 · توجّه للصفحة 44 ...
Also, we will evaluate whether the peripheral blood immune cell function is different in B/AA prostate cancer patients with metastatic disease as compared with ...
The purpose of this study is to develop prognostic and diagnostic blood ... We further examine whether blood biomarkers can ... 2-year progression free survival ( ...
FTLD is a neurodegenerative disorder of the nervous system which there are no approved treatments or cures. The study has two arms: a “longitudinal arm” ...
Scottsdale/Phoenix, Ariz., Rochester, Minn. This phase II ... This study is being done to store blood, buccal ... factors that may determine disease progression and ...
This phase II trial studies how well inotuzumab ozogamicin works in treating younger patients with CD22 positive B acute lymphoblastic leukemia that has come ...
This may be accomplished by testing and analyzing results between two cohorts: patients presenting acutely to MCF with mild COVID-19 and patients presenting ...
The purpose of this study is to look at the blood's clotting response in people who have suffered a traumatic injury and compare it with non-injured people.
لا تُقدم Mayo Clinic الدعم للشركات أو المنتجات المُعلَّن عنها هنا. لكن تدعم العائدات الإعلانية رسالتنا غير الربحية.
تحقق من هذه الكتب الأكثر مبيعًا والعروض الخاصة على الكتب والنشرات الإخبارية من Mayo Clinic Press.
تساهم التبرّعات، وهي قابلة للخصم الضريبي، في دعم آخر التطورات في الأبحاث وطرق الرعاية لإحداث نقلة نوعية في الطب.